Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.

Keywords: Follicular lymphoma; Obinutuzumab; Infusion-related reactions; Risk factors EN Follicular lymphoma Obinutuzumab Infusion-related reactions Risk factors 2795 2797 3 11/11/22 20221201 NES 221201 B Dear Editor, b The outcome of follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin's lymphoma, has been improved since the introduction of rituximab, an anti-CD20 antibody. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. [Extracted from the article]